BNP/PUT/ELI LILLY & CO/700/0.1/20.06.25 Stock

Warrant

DE000PC9XJF1

Market Closed - Boerse Frankfurt Warrants 15:50:23 2024-07-03 EDT
2.82 EUR +5.62% Intraday chart for BNP/PUT/ELI LILLY & CO/700/0.1/20.06.25
Current month+10.55%
1 month-29.25%
Date Price Change
24-07-03 2.83 +5.99%
24-07-02 2.67 +8.54%
24-07-01 2.46 -3.91%
24-06-28 2.56 -0.39%
24-06-27 2.57 -3.75%

Real-time Boerse Frankfurt Warrants

Last update July 03, 2024 at 03:50 pm

More quotes

Static data

Product typeWarrants
Buy / SellPUT
Underlying ELI LILLY AND COMPANY
IssuerLogo Issuer BNP Paribas BNP Paribas
WKN PC9XJF
ISINDE000PC9XJF1
Date issued 2024-05-15
Strike 700 $
Maturity 2025-06-20 (352 Days)
Parity 10 : 1
Emission price 4.63
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 5.49
Lowest since issue 2.41
Delta-0.16x
Omega 4.599
Premium25.51x
Gearing28.96x
Moneyness 0.7794
Difference Strike -198.1 $
Difference Strike %-28.30%
Spread 0.11
Spread %3.75%
Theoretical value 2.875
Implied Volatility 35.72 %
Total Loss Probability 74.87 %
Intrinsic value 0.000000
Present value 2.875
Break even 668.98 €
Theta-0.06x
Vega0.2x
Rho-0.12x

Company Profile

Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
More about the company

Ratings for Eli Lilly and Company

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Consensus: Eli Lilly and Company

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
898.1 USD
Average target price
870.3 USD
Spread / Average Target
-3.10%
Consensus